Phase II evaluation of vindesine in patients with non-small cell carcinoma of the lung

R. J. Gralla, B. G. Raphael, R. B. Golbey, C. W. Young

Research output: Contribution to journalArticle

43 Scopus citations

Abstract

Fifty-two patients with non-small cell carcinoma of the lung were treated iv with doses of vindesine at 3-4 mg/m2/week iv. Partial responses occurred in all histologic types in ten of 46 adequately treated patients, for an overall response rate of 22%. Patients not previously treated with chemotherapy had a higher response rate than those who had received prior chemotherapy (33% versus 12%). Reversible peripheral neuropathy occurred in all patients, and was generally of a mild to moderate degree. Mild leukopenia was seen frequently, with a median wbc nadir of 2900/mm3. As reported with the older vinca alkaloids, platelet-sparing with occasional episodes of thromboyctosis occurred with vindesine. It is concluded that vindesine is an active agent in non-small cell carcinoma of the lung and that further studies in previously untreated patients are indicated.

Original languageEnglish (US)
Pages (from-to)1343-1346
Number of pages4
JournalCancer Treatment Reports
Volume63
Issue number8
Publication statusPublished - Dec 1 1979

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gralla, R. J., Raphael, B. G., Golbey, R. B., & Young, C. W. (1979). Phase II evaluation of vindesine in patients with non-small cell carcinoma of the lung. Cancer Treatment Reports, 63(8), 1343-1346.